All Press Releases | Biogen Media

All Press Releases

TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness
4/18/16 7:30 am EDT
Biogen Data at 2016 AAN Annual Meeting Highlight Its Expansive Portfolio of MS Therapies That Meets Diverse Needs of Patients
4/12/16 7:30 am EDT
Biogen Joins Pioneering Target Validation Collaboration
2/8/16 7:00 am EST
Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MS
10/21/15 7:31 am EDT
Results from ZINBRYTA™ (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon Beta-1a Published in the New England Journal of Medicine and Presented at ECTRIMS
10/8/15 6:15 am EDT
New Data Show Strong, Sustained Effects of TECFIDERA® (Dimethyl Fumarate) in Newly-Diagnosed and Early Disease Course Multiple Sclerosis Patients
10/7/15 6:00 am EDT
Biogen to Highlight Broad Research Commitment to MS Care at ECTRIMS Congress, Including New TECFIDERA® Data Demonstrating Importance of Early Treatment
10/1/15 7:30 am EDT
FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS
4/29/15 7:30 am EDT
PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients
4/21/15 7:30 am EDT
International Survey from Biogen Identifies Opportunities for Improving MS Treatment Satisfaction
4/21/15 7:30 am EDT